Qiagen Terminates Thermo Fisher Deal After Shareholders Reject Last Offer
Executive Summary
Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.
You may also be interested in...
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Qiagen Ready To Rival Abbott With Rapid, Portable Antigen COVID-19 Test
The diagnostics company said the test is scheduled for US launch in Q4 2020.
Deal Watch: RedHill Finds New Partner For Movantik
Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.